Clinical InvestigationAcute Ischemic Heart DiseaseEthnic variation in adverse cardiovascular outcomes and bleeding complications in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) study
Section snippets
Methods
The study design8 and major findings6, 9 of the CHARISMA trial have been published previously. Briefly, patients with documented coronary artery disease, cerebrovascular disease, or peripheral arterial disease, or with multiple risk factors for atherothrombosis were enrolled and randomly assigned to clopidogrel plus aspirin or placebo plus aspirin in a double-blind fashion. Patients were excluded if they had indications or contraindications for open-label clopidogrel use or were at high risk of
Results
There were small but statistically significant differences in baseline characteristics among the 4 ethnic groups (Table I). White patients were older; more likely to have had hypercholesterolemia, previous MI, transient ischemic attacks, atrial fibrillation; and more likely to have undergone various revascularization procedures. Black patients had the highest BMI and proportion of female, were most likely to be smokers, and had hypertension, diabetes mellitus, and congestive heart failure
Discussion
The occurrence of the primary composite end point was similar among the 4 ethnic groups. However, there were important differences in the individual components of the composite end points. Compared with Asian patients, all-cause and cardiovascular mortality rates were substantially 2.56 and 1.90 times, respectively, higher for black patients, even after adjusting for differences in baseline characteristics. White patients were 1.64 times more likely than Hispanic patients to have MI. Although
Acknowledgements
The executive committee would like to acknowledge the efforts of Bernard Job, MD, and Christophe Gaudin, MD, from Sanofi-Aventis and Mel Blumenthal, MD, and Ravi Saini, MD, from Bristol-Myers Squibb on behalf of the CHARISMA trial.
References (22)
- et al.
Elevated mortality rates from circulatory disease in African American men and women of Los Angeles County, California—a possible genetic susceptibility?
Am J Med Sci
(2000) - et al.
A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial
Am Heart J
(2005) - et al.
Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial
Am Heart J
(2004) - et al.
Patients with prior myocardial infarction, stroke, or symptomatic peripheral vascular disease in the Charisma Trial
J Am Coll Cardiol
(2007) - et al.
Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study
Lancet
(2004) - et al.
Ethnic differences in the prognostic value of coronary artery calcification for all-cause mortality
J Am Coll Cardiol
(2007) - et al.
Long-term prognosis associated with coronary calcification. Observations from a registry of 25,253 patients
J Am Coll Cardiol
(2007) - et al.
Outcomes in African Americans and whites after percutaneous coronary intervention
Am J Med
(2005) - et al.
Outcome of Hispanic patients treated with thrombolytic therapy for acute myocardial infarction: Results from the GUSTO-I and -III trials
J Am Coll Cardiol
(1999) - et al.
Ethnic differences in acute myocardial infarction in Singapore
Eur Heart J
(2003)
Race and genomics
N Engl J Med
Cited by (104)
Antithrombotic Therapy After Acute Coronary Syndromes or Percutaneous Coronary Interventions in East Asian Populations
2022, JACC: AsiaCitation Excerpt :Accordingly, it has been an ongoing issue over the last decade as to whether differences in the clinical efficacy and safety of antithrombotic therapy after ACS or PCI exist between East Asian patients and other ethnic groups. Secondary analysis of the CHARISMA (Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance) trial with patients receiving aspirin and clopidogrel in multiple geographic regions has revealed that Asian populations had the lowest incidence of cardiovascular mortality, but a higher rate of bleeding events compared with other ethnic cohorts.12 Another prior study of the National Cardiovascular Data Registry database in the United States comprising 423,965 cases has also shown that patients of Asian ethnicity had more favorable clinical outcomes following PCI, including a lower rate of death and myocardial infarction (MI), compared with black or Hispanic patients.13
Implications and characteristics of high bleeding risk in East Asian patients undergoing percutaneous coronary intervention: Start with what is right rather than what is acceptable
2021, Journal of CardiologyCitation Excerpt :Kang et al. conducted an individual patient-level meta-analysis of 16 518 patients (in 7 randomized clinical trials comparing DAPT duration) and demonstrated that major adverse cardiac events occurred more frequently in non-East Asian people (0.8% vs 1.8%, p < 0.001), whereas major bleeding occurred more frequently in East Asian people (0.6% vs 0.3%, p = 0.001) [21]. Furthermore, a subanalysis of the CHARISMA (Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance) study showed that bleeding risk differed between ethnicities and that Black and Asian patients were at the highest risk of bleeding [22]. East Asian people were found to be more resistant to clopidogrel but to have fewer ischemic and more bleeding events, giving rise to the concept of the East Asian paradox, which suggests that patients from East Asia may have different appropriate therapeutic windows for platelet reactivity [23].
Cardiovascular and Bleeding Risks Associated With Nonsteroidal Anti-Inflammatory Drugs After Myocardial Infarction
2020, Journal of the American College of CardiologyPopulation-Attributable Risk Fractions for Antiplatelets and Anticoagulants in Spontaneous Intracranial Hemorrhages
2023, Cerebrovascular Diseases
The CHARISMA trial is registered with ClinicalTrials.gov, NCT00050817.